Renal imaging in patients with renal impairment

Current Urology Reports

Volumn 12, Issue 1, 2011, Pages 24-33

  Poff, Jason A ^a   Hecht, Elizabeth M ^a   Ramchandani, Parvati ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Contrast induced nephropathy; Nephrogenic systemic fibrosis; Non contrast magnetic resonance imaging

Indexed keywords

ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM MESILATE; FERUMOXYTOL; FUROSEMIDE; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED CONTRAST MEDIUM; IODIXANOL; MANNITOL; PROSTAGLANDIN E1; SODIUM CHLORIDE; THEOPHYLLINE;

ANAPHYLAXIS; ANGIOCARDIOGRAPHY; ARTICLE; BOLD SIGNAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DELAYED HYPERSENSITIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EARLY DIAGNOSIS; ECHOGRAPHY; FLUID THERAPY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; IRON DEFICIENCY ANEMIA; KIDNEY ARTERY STENOSIS; KIDNEY CARCINOMA; KIDNEY DISEASE; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MICROBUBBLE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PATHOGENESIS; POLYARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIALOADENITIS; SINGLE DRUG DOSE; SKIN ALLERGY; SPIN LABELING;

ALGORITHMS; CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79551563666     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0158-9     Document Type: Article

References (80)

1. L Kopka U Fischer G Zoeller, et al. 1997 Dual-phase helical CT of the kidney: value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma AJR Am J Roentgenol 169 1573 1578 1:STN:280:DyaK1c%2FlsVykug%3D%3D 9393168
2. MR Sun L Ngo EM Genega, et al. 2009 Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes-correlation with pathologic findings Radiology 250 793 802 10.1148/radiol.2503080995 19244046
3. MA Rosen MD Schnall 2007 Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma Clin Cancer Res 13 2 Pt 2 770s 776s 1:CAS:528:DC%2BD2sXoslWjsw%3D%3D 10.1158/1078-0432.CCR-06-1921 17255308
4. L Bokacheva H Rusinek JL Zhang VS Lee 2008 Assessment of renal function with dynamic contrast-enhanced MR imaging Magn Reson Imaging Clin N Am 16 597 611 10.1016/j.mric.2008.07.001 18926425
5. KT Tan EJ van Beek PW Brown, et al. 2002 Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis Clin Radiol 57 617 624 1:STN:280:DC%2BD38zlsVejsA%3D%3D 10.1053/crad.2002.0941 12096862 (Pubitemid 36113582)
6. •• American College of Radiology Manual on Contrast Media - Version 7. 2010. This is a continually updated, authoritative clinical guide to all contrast media issues written by experts in the radiology community.
7. JR Dillman JH Ellis RH Cohan, et al. 2007 Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults AJR Am J Roentgenol 189 1533 1538 10.2214/AJR.07.2554 18029897 (Pubitemid 350174833)
8. HH Abujudeh VK Kosaraju R Kaewlai 2010 Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32, 659 injections AJR Am J Roentgenol 194 430 434 10.2214/AJR.09.3099 20093606
9. A Li CS Wong MK Wong, et al. 2006 Acute adverse reactions to magnetic resonance contrast media-gadolinium chelates Br J Radiol 79 368 371 1:STN:280:DC%2BD283it12itA%3D%3D 10.1259/bjr/88469693 16632615 (Pubitemid 43676338)
10. SK Morcos HS Thomsen 2001 Adverse reactions to iodinated contrast media Eur Radiol 11 1267 1275 1:STN:280:DC%2BD38%2FitlCqtg%3D%3D 10.1007/s003300000778 11471623 (Pubitemid 32821379)
11. SK Morcos 2005 Review article: Acute serious and fatal reactions to contrast media: our current understanding Br J Radiol 78 686 693 1:STN:280:DC%2BD2Mzoslaqug%3D%3D 10.1259/bjr/26301414 16046418 (Pubitemid 41122680)
12. JM Idée E Pinès P Prigent C Corot 2005 Allergy-like reactions to iodinated contrast agents A critical analysis. Fundam Clin Pharmacol 19 263 281
13. RW Katzberg R Lamba 2009 Contrast-induced nephropathy after intravenous administration: fact or fiction? Radiol Clin North Am 47 789 800 10.1016/j.rcl.2009.06.002 19744594
14. RW Katzberg JH Newhouse 2010 Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 256 21 28 10.1148/radiol.10092000 20574082
15. M Rudnick H Feldman 2008 Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 3 263 272 1:CAS:528: DC%2BD1cXhs1eitbs%3D 10.2215/CJN.03690907 18178787
16. R Solomon 2009 Contrast-induced acute kidney injury (CIAKI) Radiol Clin North Am 47 783 788 10.1016/j.rcl.2009.06.001 19744593
17. JH Newhouse D Kho QA Rao J Starren 2008 Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity AJR Am J Roentgenol 191 376 382 10.2214/AJR.07.3280 18647905
18. RJ Solomon R Mehran MK Natarajan, et al. 2009 Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 4 1162 1169 10.2215/CJN.00550109 19556381
19. BR Herts E Schneider N Obuchowski, et al. 2009 Probability of reduced renal function after contrast-enhanced CT: a model based on serum creatinine level, patient age, and estimated glomerular filtration rate AJR Am J Roentgenol 193 494 500 10.2214/AJR.08.1908 19620448
20. HS Thomsen SK Morcos 2009 Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT-a pooled analysis of two randomized trials Eur Radiol 19 891 897 10.1007/s00330-008-1206-4 19002467
21. Preda L, Agazzi A, Raimondi S, et al.: Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. Eur Radiol 2010 [Epub ahead of print].
22. H Trivedi WD Foley 2010 Contrast-induced nephropathy after a second contrast exposure Ren Fail 32 796 801 1:CAS:528:DC%2BC3cXptFGmt7c%3D 10.3109/0886022X.2010.495441 20662692
23. JA Webb F Stacul HS Thomsen 2003 Morcos SK; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology: Late adverse reactions to intravascular iodinated contrast media Eur Radiol 13 181 184 10.1007/s00330-003-1874-z 12541128 (Pubitemid 38008312)
24. T Hosoya K Yamaguchi T Akutsu, et al. 2000 Delayed adverse reactions to iodinated contrast media and their risk factors Radiat Med 18 39 45 1:STN:280:DC%2BD3cvnsVKgsA%3D%3D 10852654
25. Y Gilgen-Anner M Heim HP Ledermann AJ Bircher 2007 Iodide mumps after contrast media imaging: a rare adverse effect to iodine Ann Allergy Asthma Immunol 99 93 98 10.1016/S1081-1206(10)60628-X 17650837
26. PK Donnelly B Williams EM Watkin 1993 Polyarthropathy-a delayed reaction to low osmolality angiographic contrast medium in patients with end stage renal disease Eur J Radiol 17 130 132 1:STN:280:DyaK2c%2FjvFWrtw%3D%3D 10.1016/0720-048X(93)90050-W 8223682 (Pubitemid 23303608)
27. MR Karim L Balsam S Rubinstein 2010 Permanent hearing loss with iopamidol following aortic angiography in a hemodialysis patient: a case report and review of the literature Am J Kidney Dis 55 712 716 10.1053/j.ajkd.2009.08.016 19850386
28. HS Thomsen T Almen 2002 Morcos SK; Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR): Gadolinium-containing contrast media for radiographic examinations: a position paper Eur Radiol 12 2600 2605 12271402
29. E Ledneva S Karie V Launay-Vacher, et al. 2009 Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency Radiology 250 618 628 10.1148/radiol.2503080253 19244037
30. SE Cowper M Rabach M Girardi 2008 Clinical and histological findings in nephrogenic systemic fibrosis Eur J Radiol 66 191 199 10.1016/j.ejrad.2008.01. 016 18325705
31. SE Cowper HS Robin SM Steinberg, et al. 2000 Scleromyxoedema-like cutaneous diseases in renal-dialysis patients Lancet 356 1000 1001 1:STN:280:DC%2BD3cvptVWgsw%3D%3D 10.1016/S0140-6736(00)02694-5 11041404
32. T Grobner 2006 Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 1104 1108 1:CAS:528:DC%2BD28XivVOntb8%3D 10.1093/ndt/gfk062 16431890
33. EA Sadowski LK Bennett MR Chan, et al. 2007 Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 148 157 10.1148/radiol.2431062144 17267695 (Pubitemid 46579705)
34. HH Abujudeh R Kaewlai A Kagan, et al. 2009 Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients Radiology 253 81 89 10.1148/radiol.2531082160 19709997
35. P Marckmann L Skov 2009 Nephrogenic systemic fibrosis: clinical picture and treatment Radiol Clin North Am 47 833 840 10.1016/j.rcl.2009.05.004 19744598
36. MR Prince H Zhang M Morris, et al. 2008 Incidence of nephrogenic systemic fibrosis at two large medical centers Radiology 248 807 816 10.1148/radiol.2483071863 18710976
37. • George SJ, Webb SM, Abraham JL, Cramer SP: Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010 [Epub ahead of print]. In this article is the first direct evidence of the release of gadolinium from its chelate in vivo.
38. • High WA, Ranville JF, Brown M, et al.: Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol 2010, 62:38-44. In this article, tissue correlation between amounts of deposited gadolinium and degree of fibrosis is presented.
39. M Edward JA Quinn AD Burden, et al. 2010 Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation Radiology 256 735 743 10.1148/radiol.10091131 20663970
40. NM Rofsky AD Sherry RE Lenkinski 2008 Nephrogenic systemic fibrosis: a chemical perspective Radiology 247 608 612 10.1148/radiol.2473071975 18487530
41. E Altun DR Martin R Wertman, et al. 2009 Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities Radiology 253 689 696 10.1148/radiol.2533090649 19789233
42. DR Martin SK Krishnamoorthy B Kalb, et al. 2010 Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols J Magn Reson Imaging 31 440 446 10.1002/jmri.22024 20099361
43. N Janus V Launay-Vacher S Karie, et al. 2010 Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study Eur J Radiol 73 357 359 10.1016/j.ejrad.2008.11.021 19128909
44. th Annual Scientific Symptosium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. Oral presentation. May 14, 2010.
45. SK Goergen G Rumbold G Compton C Harris 2010 Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin Radiology 254 261 269 10.1148/radiol.09090690 20032157
46. BF Sena JP Stern PV Pandharipande, et al. 2010 Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire AJR Am J Roentgenol 195 424 428 10.2214/AJR.09.3803 20651199
47. SD Weisbord PM Palevsky 2008 Prevention of contrast-induced nephropathy with volume expansion Clin J Am Soc Nephrol 3 273 280 1:CAS:528: DC%2BD1cXhs1eitbg%3D 10.2215/CJN.02580607 17989201
48. JH Ellis RH Cohan 2009 Prevention of contrast-induced nephropathy: an overview Radiol Clin North Am 47 801 811 10.1016/j.rcl.2009.06.003 19744595
49. P Meier DT Ko A Tamura, et al. 2009 Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis BMC Med 7 23 10.1186/1741-7015-7-23 19439062
50. SD Navaneethan S Singh S Appasamy, et al. 2009 Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis Am J Kidney Dis 53 617 627 1:CAS:528:DC%2BD1MXnslKrsbw%3D 10.1053/j.ajkd.2008.08.033 19027212
51. SS Brar S Hiremath G Dangas, et al. 2009 Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 1584 1592 1:CAS:528:DC%2BD1MXhtlGgur%2FK 10.2215/CJN.03120509 19713291
52. EA Hoste JJ De Waele SA Gevaert, et al. 2010 Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis Nephrol Dial Transplant 25 747 758 1:CAS:528:DC%2BC3cXislajt78%3D 10.1093/ndt/gfp389 19703838
53. S Zoungas T Ninomiya R Huxley, et al. 2009 Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy Ann Intern Med 151 631 638 19884624
54. M Kanbay A Covic SG Coca, et al. 2009 Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials Int Urol Nephrol 41 617 627 1:CAS:528:DC%2BD1MXns1Cgurg%3D 10.1007/s11255-009-9569-2 19396567
55. Cho R, Javed N, Traub D, et al.: Oral Hydration and Alkalinization is Noninferior to Intravenous Therapy for Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease. J Interv Cardiol 2010 [Epub ahead of print].
56. Trivedi H, Daram S, Szabo A, et al.: High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009, 122:874.e9-15.
57. PA Poletti P Saudan A Platon, et al. 2007 I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity AJR Am J Roentgenol 189 687 692 10.2214/AJR.07.2356 17715118 (Pubitemid 47328553)
58. S Goldfarb PA McCullough J McDermott SB Gay 2009 Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology Mayo Clin Proc 84 170 179 10.4065/84.2.170 19181651
59. TG Gleeson S Bulugahapitiya 2004 Contrast-induced nephropathy AJR Am J Roentgenol 183 1673 1689 15547209
60. P Kandula R Shah N Singh, et al. 2010 Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention Nephrology (Carlton) 15 165 170 1:CAS:528: DC%2BC3cXltl2qt78%3D 10.1111/j.1440-1797.2009.01204.x
61. SH Jo BK Koo JS Park, et al. 2009 N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial Am Heart J 157 576 583 1:CAS:528:DC%2BD1MXisVOlt7g%3D 10.1016/j.ahj.2008.11.010 19249432
62. JI Silberzweig M Chung 2009 Removal of gadolinium by dialysis: review of different strategies and techniques J Magn Reson Imaging 30 1347 1349 10.1002/jmri.21981 19937933
63. MC Heinrich L Häberle V Müller, et al. 2009 Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials Radiology 250 68 86 10.1148/radiol.2501080833 19092091
64. SK Morcos HS Thomsen 2008 Nephrogenic systemic fibrosis: more questions and some answers Nephron Clin Pract 110 c24 31 1:STN:280:DC%2BD1cnhvVCiug%3D%3D 10.1159/000151228 18688172
65. SK Verma DG Mitchell R Yang, et al. 2010 Exophytic renal masses: angular interface with renal parenchyma for distinguishing benign from malignant lesions at MR imaging Radiology 255 501 507 10.1148/radiol.09091109 20160001
66. A Qayyum 2009 Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications Radiographics 29 1797 1810 10.1148/rg.296095521 19959522
67. J Zhang YM Tehrani L Wang, et al. 2008 Renal masses: characterization with diffusion-weighted MR imaging-a preliminary experience Radiology 247 458 464 10.1148/radiol.2472070823 18430878
68. B Taouli RK Thakur L Mannelli, et al. 2009 Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging Radiology 251 398 407 10.1148/radiol.2512080880 19276322
69. S Kim M Jain AB Harris, et al. 2009 T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging Radiology 251 796 807 10.1148/radiol.2513080724 19380690
70. K Sandrasegaran CP Sundaram R Ramaswamy, et al. 2010 Usefulness of diffusion-weighted imaging in the evaluation of renal masses AJR Am J Roentgenol 194 438 445 10.2214/AJR.09.3024 20093607
71. Wang H, Cheng L, Zhang X, et al.: Renal cell carcinoma: Diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 2010 epub ahead of print.
72. G Manenti M Di Roma S Mancino, et al. 2008 Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T Radiol Med 113 199 213 1:STN:280:DC%2BD1czpsFWktQ%3D%3D 10.1007/s11547-008-0246-9 18386122 (Pubitemid 351666954)
73. GJ Wilson JH Maki 2009 Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla Magn Reson Imaging Clin N Am 17 13 27 10.1016/j.mric.2009. 01.002 19364597
74. H Chandarana V Lee 2009 Renal functional MRI: are we ready for clinical application? AJR 192 1550 1557 10.2214/AJR.09.2390 19457818
75. T Yoshikawa H Kawamitsu DG Mitchell, et al. 2006 ADC measurement of abdominal organs and lesions using parallel imaging technique AJR Am J Roentgenol 187 1521 1530 10.2214/AJR.05.0778 17114546 (Pubitemid 44788683)
76. Artz NS, Sadowski EA, Wentland AL, et al.: Arterial spin labeling MRI for assessment of perfusion in native and transplanted kidneys. Magn Reson Imaging 2010 [Epub ahead of print].
77. PL Choyke H Kobayashi 2006 Functional magnetic resonance imaging of the kidney using macromolecular contrast agents Abdom Imaging 31 224 231 1:STN:280:DC%2BD287nslGjtg%3D%3D 10.1007/s00261-005-0390-9 16283582
78. A Morell H Ahlstrom SO Schoenberg, et al. 2008 Quantitative renal cortical perfusion in human subjects with magnetic resonance imaging using iron-oxide nanoparticles: influence of T1 shortening Acta Radiol. 49 955 962 1:STN:280:DC%2BD1cngslWkuw%3D%3D 10.1080/02841850802227139 18615336
79. EA Neuwelt BE Hamilton CG Varallyay, et al. 2009 Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 75 465 474 1:CAS:528:DC%2BD1MXit1Wntrw%3D 10.1038/ki.2008.496 18843256
80. SR Wilson PN Burns 2010 Microbubble-enhanced US in body imaging: what role? Radiology 257 24 39 10.1148/radiol.10091210 20851938